We suggest that pharmacologically targeting autophagy or gene therapy for autophagy-related genes such as mTOR, LC3, Beclin-1, p62, or other ATG genes are potential therapeutic options for degenerative disc diseases. This evidence concerns the gene BECN1 and intervertebral disk degenerative disorder.